Trinity Biotech has signed a collaboration agreement with the University at Buffalo to codevelop and commercialize a suite of proprietary biomarkers for Sjögren’s Syndrome, licensed through its IMMCO subsidiary. The company’s NYSDOH-approved reference laboratory will serve as the initial launch platform, reinforcing its strategy to build a differentiated specialty diagnostic portfolio focused on high-value assays.

The biomarker suite targets early-stage and seronegative Sjögren’s patients, aiming to improve diagnostic speed, accuracy and clinical confidence compared with subjective symptom reporting and invasive tests. The partnership leverages UB faculty research and UB CAT funding to advance a new generation of objective tests capable of detecting disease before significant glandular damage occurs.

Sjögren’s Syndrome affects an estimated 4 million people in the U.S., predominantly women, and is often misdiagnosed as other autoimmune conditions. This collaboration expands Trinity Biotech’s autoimmune diagnostics pipeline and is expected to drive downstream benefits including clinical partnerships, payer data packages and a strengthened platform for future biomarker commercialization.